A study by Kowalik et al. suggests that re-activation of the thyroid hormone triiodothyronine (T3)/thyroid hormone receptor β (TRβ) axis induces differentiation of neoplastic cells towards a more benign phenotype and that T3 or its analogues, particularly agonists of the TRβ, can represent useful tools in liver cancer therapy. Here, THRB is linked to liver cancer.